Sign In
Learn bits
Health & Medicine
Mahesh

02/11/23 09:30 AM IST

India’s own CAR-T cell therapy

In News
  • The Central Drugs Standard Control Organisation (CDSCO) this month granted market authorisation for NexCAR19, India’s first indigenously-developed CAR-T cell therapy, to ImmunoACT, a company incubated by IIT Bombay.
CAR-T cell therapy
  • CAR-T is a revolutionary therapy that modifies immune cells, specifically T-cells, by turning them into potent cancer fighters known as CAR-T cells.
  • T-cells are special cells (white blood cells that find and fight illness and infection) whose primary function is cytotoxic, meaning it can kill other cells. In CAR-T therapy, we genetically modify them into cancer-fighting cells.
  • These supercharged cells are then put back into the body, and they go after cancer cells — especially in blood cancers like leukaemia and lymphomas.
  • While chemotherapy and immunotherapy may add a few months or years to a cancer patient’s life, cell-and-gene therapy is designed to cure and provide lifelong benefit.
  • It makes treatment easier with a one-time therapy [unlike several sessions of chemotherapy] that can be truly transformative [for a patient]. It’s a lifeline for non-responsive cancer patients.
NexCar19
  • NexCar19 is a type of CAR-T and gene therapy developed indigenously in India by ImmunoACT, which is a company incubated at IIT Bombay.
  • Our therapy is designed to target cancer cells that carry the CD19 protein.
  • This protein acts like a flag on cancer cells, which allows CAR-T cells to recognise and attach themselves to the cancer cells and start the process of elimination.
  • Even some developed nations don’t have their own CAR-T therapies; they import them from the United States or Europe.
  • India is now one of the first developing countries to have its indigenous CAR-T and gene therapy platform.
Who can get benefit from NexCar19 therapy?
  • The therapy is for people with B-cell lymphomas who didn’t respond to standard treatments like chemotherapy, leading to relapse or recurrence of the cancer.
  • The patient’s journey starts with a doctor’s prescription at the clinic, followed by donation of blood by the patient at a transfusion centre.
  • The blood goes to the lab, where the T-cells are genetically modified.
  • In a week to 10 days, these cells return to the clinic for patient reinfusion.
  • Essentially, patients only need to give a blood sample at their clinic, and come back in 7-10 days for reinfusion.
  • Recovery typically occurs within two weeks after one cycle of the treatment.
  • In our data, approximately 70% of patients respond to the treatment, with variations between leukaemia and lymphoma cases.
  • About 50% of these responsive patients achieve a complete response.
Cost pf the therapy
  • Currently, we are looking at a price range of Rs 30-40 lakh for CAR-T therapy, which we intend to hold. Even at this cost, it may not be accessible to everyone.
  • Our ultimate goal is to bring the cost down to Rs 10-20 lakh.
  • As technology matures and manufacturing processes improve, we anticipate that the cost will decrease.
Source- Indian Express

More Related Current Affairs View All

05 May

Key objectives of caste count

'The Union Cabinet has decided that the next Census will include questions on caste to its enumeration of India’s population, for the first time in almost a century. ' T

Read More

05 May

2 new genome-edited rice varieties

'Agriculture Minister Shivraj Singh Chouhan recently released two genome-edited varieties of rice, the first achievement of its kind in the country.' These two varieties, which

Read More

05 Mar

First-ever comprehensive survey of India’s river dolphins

'Prime Minister Narendra Modi released the results of the first-ever comprehensive population estimation of riverine dolphins – Gangetic and Indus dolphins – done in In

Read More

India’s First Ai-Driven Magazine Generator

Generate Your Custom Current Affairs Magazine using our AI in just 3 steps